基于计算机的停药策略的有效性,以减少PPI处方:一个多中心集群随机控制试验
Julia Heisig1, Bettina Bücker2, Alexandra Schmidt3
1Department of Primary Care, University of Marburg, Marburg, Germany. julia.heisig@uni-marburg.de.
Scientific reports
|December 7, 2023
概括
电子工具 arriba-PPI有效地减少了长期的质子抑制剂 (PPI) 在初级保健中的使用. 这种决策辅助工具有助于全科医生和患者讨论和去处方不必要的PPI药物,改善患者的治疗结果.
科学领域:
- 主要护理医学 医疗保健
- 临床决策支持系统 临床决策支持系统
- 药物治疗 药物治疗
背景情况:
- 长期使用质子抑制剂 (PPI) 为全科医生带来了令人丧的挑战.
- 需要有效的工具来指导PPI在初级保健机构的处方.
研究的目的:
- 评估电子决策辅助工具,api-PPI在减少长期PPI摄入方面的有效性.
- 评估阿比塔-PPI对PPI处方率在初级保健中的影响.
主要方法:
- 一项随机对照试验,涉及至少6个月服用PPI的患者.
- 干预组接受了阿比达-PPI的咨询;对照组接受了通常的护理.
- 在干预前6个月和干预后12个月内监测PPI处方.
主要成果:
- 与阿比卡-PPI的商导致PPI定义的每日剂量 (DDD) 在6个月后减少22.3% (p < 0.0001).
- 在干预组中,PPI DDD的减少在12个月内仍然显著.
- 对照组在12个月后 (-10.2%) 显示PPI DDD的减少较小.
结论:
- 上方PPI电子决策辅助器在减少长期PPI在初级保健中的使用方面是有效的.
- arriba-PPI促进了全科医生和患者之间关于PPI风险和绝用药的讨论.
- 该工具支持不再处方不必要的PPI药物,增强初级保健实践.
相关概念视频
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
435
Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
435
Peptic Ulcer Disease IV: Management
95
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
95
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
411
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
411
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
487
Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
487
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
208
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
208
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
153
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
153


